What are the typical symptoms of ankylosing spondylitis and what are the recommended treatment options?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ankylosing Spondylitis: Symptoms and Treatment

Typical Symptoms

Ankylosing spondylitis presents with inflammatory back pain characterized by nocturnal awakening, prolonged morning stiffness (lasting >30 minutes), improvement with exercise but not rest, and diurnal variation with symptoms worse in early morning 1.

Key clinical features include:

  • Axial manifestations: Chronic lower back pain and stiffness affecting the sacroiliac joints and spine, potentially progressing to spinal fusion and postural deformity 2
  • Peripheral manifestations: Enthesitis (inflammation at tendon/ligament insertion sites), peripheral arthritis (particularly oligoarthritis), and dactylitis 3
  • Extra-articular manifestations: Acute anterior uveitis (eye inflammation), inflammatory bowel disease, psoriasis, and aortitis 2
  • Systemic symptoms: Fatigue and functional impairment comparable to rheumatoid arthritis 1

The disease typically manifests in males during their third decade, though women are increasingly recognized 2.

Treatment Algorithm

First-Line Treatment: NSAIDs

For patients with active ankylosing spondylitis, NSAIDs are strongly recommended as initial pharmacological management 3, 4. No particular NSAID is preferred over another 4.

  • For active disease: Continuous NSAID therapy is conditionally recommended over on-demand use to control symptoms 3, 4
  • For stable disease: On-demand NSAID use is strongly recommended over continuous treatment 3
  • NSAID failure definition: Consider treatment failure after 1 month of continuous use (at least two different NSAIDs for 15 days each) 3

Important caveat: Continuous NSAIDs should be used for symptom control only, not to prevent structural progression, as evidence for radiographic benefit is inconsistent 3. Use selective COX-2 inhibitors when available in patients at high risk for adverse events 3.

Second-Line Treatment: Biologic DMARDs

For patients with active disease despite NSAIDs (ASDAS ≥2.1) who have failed ≥2 NSAIDs AND demonstrate either elevated CRP, MRI inflammation of sacroiliac joints, or radiographic sacroiliitis, initiate biologic therapy with either TNF inhibitors or IL-17 inhibitors 5.

Biologic Selection Strategy:

Current practice is to start with a TNF inhibitor or IL-17 inhibitor as first-line biologic therapy 5. The choice should be guided by extra-articular manifestations:

  • TNF monoclonal antibodies (infliximab, adalimumab, certolizumab, golimumab): Preferred for patients with recurrent acute anterior uveitis or inflammatory bowel disease 5
  • IL-17 inhibitors (secukinumab, ixekizumab): Preferred for patients with significant psoriasis 5
  • TNF inhibitors are conditionally recommended over IL-17 inhibitors when extra-articular features are absent 4

Available TNF inhibitors include infliximab, etanercept, adalimumab, certolizumab, golimumab, and their biosimilars, with no particular agent preferred 4.

Third-Line: Biologic Switching

If the first biologic fails, the approach depends on the type of failure:

  • Primary non-response to TNFi (no improvement within 3-6 months): Switch to secukinumab or ixekizumab conditionally recommended over switching to another TNFi 4
  • Secondary non-response to TNFi (loss of response after initial benefit): Switch to a different TNFi conditionally recommended over non-TNFi biologics 4
  • Strongly recommend against switching to a biosimilar of the same TNFi that failed 4

Role of Conventional Synthetic DMARDs

Sulfasalazine or methotrexate should be considered ONLY in patients with prominent peripheral arthritis or when TNF inhibitors are not available 4. These agents are conditionally recommended but have very low to moderate evidence for pure axial disease 4.

Tofacitinib (JAK inhibitor) is conditionally recommended but ranks below TNFi and IL-17 inhibitors in the treatment hierarchy 4.

Treatments to Avoid

Long-term systemic glucocorticoids are strongly recommended against in axial spondyloarthritis 3. Local glucocorticoid injections may be conditionally used for isolated active sacroiliitis, enthesitis, or monoarthritis/oligoarthritis despite NSAIDs 3.

Non-Pharmacological Management

Physical therapy with consistent exercise, stretching, and posture maintenance is essential 2. Patients should be managed with experts in physical medicine and rehabilitation 3.

Monitoring Strategy

Monitor disease activity at regular intervals using ASDAS (Ankylosing Spondylitis Disease Activity Score) and/or SASDAS, along with CRP and/or ESR 3. The treatment target is remission or sustained low disease activity 3.

Routine MRI or radiographic studies for follow-up are strongly recommended against 3—imaging should be reserved for diagnostic purposes or specific clinical questions, not routine monitoring.

Stable Disease Management

For patients achieving stable disease on biologics, continue the biologic alone and stop NSAIDs 4. Tapering (rather than immediate discontinuation) can be considered in patients with sustained remission 5.

Critical Pitfalls

  • Do not delay biologic therapy in patients meeting criteria—early intervention improves outcomes
  • Evaluate for extra-articular manifestations before selecting biologics, as this significantly impacts drug choice
  • If treatment fails, re-evaluate the diagnosis and assess for comorbidities before switching agents 5
  • Bone metabolism evaluation and fracture risk assessment with validated methods is strongly recommended given increased osteoporosis risk 3

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.